Alzheimer's Disease
Low Blood Pressure Shows Strongest Link to Alzheimer's Risk in New Analysis of Nearly 800,000 Adults
A new study in the Journal of the American Heart Association finds that hypotension is most strongly associated with Alzheimer's disease among several cardiovascular conditions, with stronger effects in Black and Hispanic adults, suggesting shared biological roots.
Annovis Bio Announces Public Offering to Fund Buntanetap Alzheimer's Trial
Annovis Bio has proposed a public offering of common stock and warrants to raise capital for its Phase 3 Alzheimer's study and general corporate purposes.
Annovis Bio Achieves 85% Enrollment in Phase 3 Alzheimer’s Trial, Advances Parkinson’s Program
Annovis Bio reports first-quarter progress with 85% enrollment in its pivotal Phase 3 Alzheimer's trial and 40% enrollment in its Parkinson's open-label study, signaling potential regulatory milestones for buntanetap.
Oncotelic Therapeutics Featured in Editorial Highlighting Intranasal Drug Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics' intranasal nose-to-brain delivery platform, featured in a BioMedWire editorial, addresses key challenges in CNS drug delivery for Alzheimer's disease and biodefense research by bypassing the blood-brain barrier.
Oncotelic Therapeutics Completes $12.5M Asset Transfer to Lunai Bioworks, Focusing on Nose-to-Brain Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics has transferred worldwide rights to its nose-to-brain delivery system for Alzheimer's and biodefense to Lunai Bioworks in exchange for $12.5 million in preferred stock, enabling it to monetize assets while retaining control for other indications like Parkinson's disease.
Memory Beads Inspired by 116-Year-Old's Habit Launch to Support Alzheimer's Research
A new tactile brain health tool called Peter's Memory Beads, inspired by a 116-year-old man's daily routine, has launched with all proceeds supporting Alzheimer's Association research and services.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Trial Progress and Promising Biomarker Data
Annovis Bio reports significant progress in its Phase 3 Alzheimer's trial with full site activation and promising biomarker data showing buntanetap's disease-modifying potential, positioning the company for potential regulatory submission.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments
Alpha Cognition's participation in the Spartan Capital Securities investor conference provides a platform to showcase its innovative treatments for Alzheimer's and cognitive impairment from traumatic brain injury, potentially attracting crucial investment for addressing unmet medical needs.
Alpha Cognition Secures $35 Million in Oversubscribed Public Offering to Accelerate Neurodegenerative Disease Treatment Commercialization
Alpha Cognition's successful $35 million public offering will accelerate commercialization of its Alzheimer's treatment ZUNVEYL and advance development of other neurodegenerative disease therapies, addressing critical unmet medical needs.
Annovis Bio Inc. Advances Phase 3 Alzheimer’s Trial and Reports Q2 2025 Financial Results
Annovis Bio Inc. (NYSE: ANVS) makes significant progress in its Phase 3 Alzheimer’s trial and reports improved financial results for Q2 2025, highlighting the potential impact of its neurodegenerative disease therapies.
Alpha Cognition Inc. Advances Alzheimer's Treatment with ZUNVEYL, Secures Key Regulatory Milestones
Alpha Cognition Inc. reports significant progress in the commercialization of ZUNVEYL for Alzheimer's disease, highlighting early adoption in the U.S. long-term care market and a key regulatory achievement in China.
InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer's Treatment
InMed Pharmaceuticals Inc. announces positive preclinical results for INM-901, showing potential in reducing neuroinflammation associated with Alzheimer's disease, independent of amyloid beta or tau pathology.
Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates
Annovis Bio Inc. (NYSE: ANVS) is set to host a webcast featuring CEO Maria Maccecchini, Ph.D., to discuss updates on its Phase 3 trial for early Alzheimer’s disease and FDA feedback on its Parkinson’s disease program, highlighting the company's progress in neurodegenerative disease treatments.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Clinical Trial
Annovis Bio has initiated a pivotal Phase 3 clinical trial for buntanetap, a potential treatment for early Alzheimer's disease, with the potential to address symptomatic and disease-modifying aspects of the condition.
Dr. Nupur Ghoshal Receives Alois Alzheimer Award for Groundbreaking Dementia Research
Dr. Nupur Ghoshal, a distinguished neurologist and researcher at Washington University School of Medicine, has been honored with the prestigious Alois Alzheimer Award for her significant contributions to understanding and advancing Alzheimer's and dementia research.
Stonegate Initiates Coverage on Alpha Cognition, Projects Strong Growth for New Alzheimer's Drug
Alpha Cognition's newly approved Alzheimer's drug ZUNVEYL is positioned to address a significant market gap with a potentially safer treatment option, as Stonegate Capital Partners initiates coverage with a valuation range of $27.62 to $38.44 per share.